Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2012

01-01-2012 | Breast Oncology

Outcomes for Patients who Develop Both Breast and Colorectal Cancer

Authors: Carla S. Fisher, MD, Mitchell S. Wachtel, MD, Julie A. Margenthaler, MD

Published in: Annals of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

Patients diagnosed with both breast and colorectal cancer are not uncommon and will likely be seen more often as the population ages and treatment modalities improve. Survival outcomes for such patients have not been previously reported.

Methods

The 1988–2007 Surveillance, Epidemiology, and End Results data were used to identify women diagnosed with both breast and colorectal cancer. Disease-specific survival rates were compared.

Results

We identified 4,835 women who were diagnosed with both breast and colorectal cancer. Of these, 2,844 (58.8%) were diagnosed with breast cancer first and 1,807 (37.4%) were diagnosed with colorectal cancer first; 184 (3.8%) had synchronous cancers. At 5 years following the second cancer diagnosis, 163 (3.4%) died of breast cancer and 477 (9.9%) died of colorectal cancer (P < 0.05). Comparing primary site groups between years 1 and 5 after the second cancer diagnosis showed that the relative risk of death from breast cancer declined by 46%, though it did not reach statistical significance (P = 0.24), while it significantly increased by 46% for colorectal cancer death (P = 0.0004). These findings persisted regardless of patient age, stage at diagnosis, or breast tumor histology.

Conclusion

For women diagnosed with both breast and colorectal cancer, the cumulative risk of death at 5 years following the second cancer diagnosis is 3 times more likely to be due to colorectal cancer than to breast cancer. Colorectal cancer specific mortality increases with time, while breast cancer specific mortality decreases with time. Consideration should be given to these findings when discussing prognosis and making treatment decisions.
Literature
4.
go back to reference Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009;45:3000–7.PubMedCrossRef Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009;45:3000–7.PubMedCrossRef
5.
go back to reference Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855–61.PubMed Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855–61.PubMed
6.
go back to reference Bernstein JL, Lapinski RH, Thakore SS, Doucette J, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14:552–8.PubMedCrossRef Bernstein JL, Lapinski RH, Thakore SS, Doucette J, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14:552–8.PubMedCrossRef
7.
go back to reference Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88:2739–50.PubMedCrossRef Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88:2739–50.PubMedCrossRef
8.
go back to reference Bernstein JB, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992;136:925–36.PubMed Bernstein JB, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992;136:925–36.PubMed
9.
go back to reference Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer. 2003;89:513–8.PubMedCrossRef Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer. 2003;89:513–8.PubMedCrossRef
10.
go back to reference Diaz R, Munarriz B, Santaballa A, Palomar L, Montalar J. Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience. Med Oncol. 2010. doi:10.1007/s12032-010-9785-8. Diaz R, Munarriz B, Santaballa A, Palomar L, Montalar J. Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience. Med Oncol. 2010. doi:10.​1007/​s12032-010-9785-8.
11.
go back to reference Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25:4210–6.PubMedCrossRef Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25:4210–6.PubMedCrossRef
12.
go back to reference Bouvier AM, Latournerie M, Jooste V, Lepage C, Cottet V, Faivre J. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer. 2008;44:522–7.PubMedCrossRef Bouvier AM, Latournerie M, Jooste V, Lepage C, Cottet V, Faivre J. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer. 2008;44:522–7.PubMedCrossRef
13.
go back to reference Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100:252–60.PubMedCrossRef Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100:252–60.PubMedCrossRef
14.
go back to reference Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011;29;1146–50.PubMedCrossRef Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011;29;1146–50.PubMedCrossRef
15.
go back to reference Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States. Cancer Cause Control. 2004;15:1027–34.CrossRef Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States. Cancer Cause Control. 2004;15:1027–34.CrossRef
Metadata
Title
Outcomes for Patients who Develop Both Breast and Colorectal Cancer
Authors
Carla S. Fisher, MD
Mitchell S. Wachtel, MD
Julie A. Margenthaler, MD
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1843-8

Other articles of this Issue 1/2012

Annals of Surgical Oncology 1/2012 Go to the issue